Hem › Prostatacancer › Virginia › Charlottesville
Kliniska studier för Prostatacancer i Charlottesville, VA
15 studier för Prostatacancer söker deltagare vid platser i och runt Charlottesville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RekryterarFas 3
- University of Virginia Health System ( Site 0054), Charlottesville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RekryterarFas 3
- University of Virginia Comprehensive Cancer Center, Charlottesville
- University of Virginia, Charlottesville
- UVA Health Cancer Care Pantops, Charlottesville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekryterarFas 3
- University of Virginia Cancer Center, Charlottesville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RekryterarFas 2
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
RekryterarFriska volontärer välkomna
- Sentara Martha Jefferson Hospital, Charlottesville
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RekryterarFas 3
- University of Virginia Cancer Center, Charlottesville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RekryterarFas 2
- University of Virginia Comprehensive Cancer Center, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- University of Virginia, Charlottesville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekryterarFas 3
- University of Virginia Cancer Center, Charlottesville
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
RekryterarFas 1/2
- University of Virginia, Charlottesville
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
Rekryterar
- University of Virginia Health System, Charlottesville
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
RekryterarObservationsstudie
- University of Virginia, Charlottesville
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
Rekryterar
- University of Virginia, Charlottesville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RekryterarFas 1
- University of Virginia Cancer Center, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Charlottesville
Prostatacancer-studier i andra städer
- New York City, NY103 studier
- Houston, TX76 studier
- Los Angeles, CA61 studier
- Boston, MA59 studier
- St. Louis, MO46 studier
- Chicago, IL45 studier
- San Francisco, CA45 studier
- Philadelphia, PA44 studier
- Baltimore, MD43 studier
- Nashville, TN42 studier
- Seattle, WA42 studier
- Washington, DC38 studier
Andra studier i Charlottesville
- Icke-småcellig lungcancer21 studier
- Akut myeloid leukemi16 studier
- Metastaserande cancer13 studier
- Endometriecancer13 studier
- Cancer (alla typer)13 studier
- Lungcancer13 studier
- Hjärtsvikt11 studier
- Äggstockscancer10 studier
- Kolorektal cancer10 studier
- Typ 1-diabetes9 studier
- Bröstcancer9 studier
- Bukspottkörtelcancer9 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.